Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
Prathap Nagaraja Shastri(Springhouse), Alison Betts(Takeda (United States)), Martin Lechmann(Roche Pharma AG (Germany)), Xirong Zheng(Bristol-Myers Squibb (United States)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Marc W. Retter(Regeneron (United States)), Yanguang Cao(University of North Carolina at Chapel Hill), M. Naveed Shaik(Pfizer (United States)), Kaushik Datta(Bristol-Myers Squibb (United States)), John M. Burke(Certara (United States)), Christophe Boetsch(Roche (Switzerland)), Kapil Gadkar, Fei Hua(Center for Cancer Research), Nirav N. Shah(Medical College of Wisconsin), Jun Wang(Wuhan University of Science and Technology), Min Zhu(Second Military Medical University), Tommy Li(Genmab (United States)), Meric Ovacik, Hardik Mody(Kaiser Permanente South San Francisco Medical Center), Vijay Upreti(Amgen (United States))
Cited by 9
Related Papers
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
The Noncoding RNA Expression Profile and the Effect of lncRNA AK126698 on Cisplatin Resistance in Non-Small-Cell Lung Cancer Cell
|PLoS ONE|2013|264
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213
Ischemic postconditioning protects remodeled myocardium via the PI3K–PKB/Akt reperfusion injury salvage kinase pathway
|Cardiovascular Research|2006|155